AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32664003
Drug: Combining sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combining sertraline with mirtazapine
Trial: 32664003
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to mirtazapine after initial failure to remit on sertraline
Trial: 35550149
Drug: Oral Veillonella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Veillonella nakazawae
Trial: 32741031
Drug: Warfarin (775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (775 patients, INR goal 2.5)
Trial: 33405993
Drug: TQ‐A3334 (0.2‐1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ‐A3334 (0.2‐1.8 mg)
Trial: 33405993
Drug: TQ‐A3334 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ‐A3334 (1.0 to 1.8 mg)
Trial: 33405993
Drug: TQ‐A3334 (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ‐A3334 (1.2 mg) with food
Trial: 33554566
Drug: Low vitamin-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low vitamin-D levels (<50 nmol/L)
Trial: 33554566
Drug: Normal vitamin-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal vitamin-D levels (>50 nmol/L)
Trial: 34674368
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg time-release melatonin
Trial: 33028293
Drug: Reduced duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced duration of antibiotic treatment
Trial: 33028293
Drug: Standard duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard duration of antibiotic treatment (control group)
Trial: 34819131
Drug: Lithium (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (300 mg)
Trial: 32524888
Drug: Elective replacement
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective replacement of peripheral intravenous cannula (72–96 h)
Trial: 32524888
Drug: Standard replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard replacement of peripheral intravenous cannula
Trial: 32524888
Drug: Elective replacement
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective replacement of peripheral intravenous cannula
Trial: 36453237
Drug: Water Vapor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water Vapor Therapy (Rezum procedure)
Trial: 35507830
Drug: Exposure-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based treatment for perfectionism
Trial: 36857393
Drug: ATG 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG 4.5 mg/kg
Trial: 34275562
Drug: Memantine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 20 mg every 8 hours for five days, then 20 mg daily for three months
Trial: 35392744
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg once daily
Trial: 36203828
Drug: Home-based transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based transcranial direct current stimulation (tDCS) self-administered daily for 30 min with 2 mA
Trial: 35454326
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (C) with perioperative opioids and metamizole/acetaminophen
Trial: 35377106
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard care with swaddling, oral sucrose, and sucking)
Trial: 33038825
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (200 mg/kg)
Trial: 33038825
Drug: Betaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (2 g/kg)
Trial: 33038825
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ascorbic acid (200 mg/kg) and Betaine (2 g/kg)
Trial: 36103158
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg/d
Trial: 36103158
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg/d
Trial: 34312921
Drug: 3 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml/kg 5% Dextrose
Trial: 34312921
Drug: 5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml/kg 5% Dextrose
Trial: 33389390
Drug: Emotion coaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotion coaching parenting intervention (Tuning in to Kids® program), 6 weekly sessions
Trial: 34329897
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil (GE) 600 mg
Trial: 32694214
Drug: Dapagliflozin/Saxagliptin (DAPA/SAXA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin/Saxagliptin (DAPA/SAXA) 10/5 mg
Trial: 32144165
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin (DAPA) 10 mg
Trial: 32043211
Drug: Suramin (P2Y2R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin (P2Y2R inhibitor, 100 μM)
Trial: 32991462
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.1 mg)
Trial: 34696892
Drug: Regorafenib at
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib at 160 or 120 mg daily, 3 weeks on/1 week off
Trial: 34696892
Drug: Tamoxifen at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen at 40 mg daily
Trial: 33827639
Drug: Prebiotic (oligofructose‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic (oligofructose‐enriched inulin; 16 g/day)
Trial: 33985385
Drug: -40 mmHg
RxNorm normalized name: Loving Comfort Knee High 30-40 mmHg Beige L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -40 mmHg INP treatment for 1 hour twice daily for 12 weeks
Trial: 33985385
Drug: -10 mmHg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -10 mmHg INP sham control treatment for 1 hour twice daily for 12 weeks
Trial: 39536246
Drug: Antioxidant supplements
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplements
Trial: 36484214
Drug: Xience drug-eluting
RxNorm normalized name: Ruxience
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Xience drug-eluting stent (DES)
Trial: 33756301
Drug: Cigalike (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigalike (18 mg/mL)
Trial: 33756301
Drug: Tank (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tank (18 mg/mL)
Trial: 33756301
Drug: Tank (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tank (6 mg/mL)
Trial: 34622734
Drug: CET monotherapy
RxNorm normalized name: CET
DrugBank: Cefalotin (DB00456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CET monotherapy
Trial: 34622734
Drug: AAU monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAU monotherapy
Trial: 34622764
Drug: Apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 30 mg twice daily for 12 weeks, followed by continued treatment through Week 64
Trial: 32414338
Drug: Management algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management algorithm including extended focused assessment of sonography for HIV and tuberculosis (eFASH) in combination with chest X-ray and microbiological tests.
Trial: 34974413
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg OD)
Trial: 33539318
Drug: Tripterygium glycosides
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium glycosides (TG) 20 mg tablet three times per day for 24 weeks
Trial: 33539318
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (iv.MP) 500 mg once per week for 6 weeks followed by 250 mg per week for 6 weeks
Trial: 33539318
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (iv.MP)
Trial: 33235030
Drug: Dapansutrile 2000
RxNorm normalized name: Dapansutrile
DrugBank: Dapansutrile (DB16130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapansutrile 2000 mg
Trial: 34574458
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) - Angelicae Sinensis Radix
Trial: 34574458
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) - Astragali Radix
Trial: 34574458
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) - Salviae Miltiorrhizae Radix et Rhizoma
Trial: 32429737
Drug: Tart Cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart Cherry Juice (240 mL, twice daily for 12 weeks)
Trial: 32429737
Drug: Control (isocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isocaloric placebo drink, twice daily for 12 weeks)
Trial: 36575506
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of a clear supplement containing 10 g of whey protein and 54 g of carbohydrates (WP+CHO)
Trial: 36575506
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of a clear supplement containing 12.5% maltodextrin (25 g) (CHO)
Trial: 36064604
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of ABCB5+ mesenchymal stem cells (MSCs)
Trial: 34128498
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (plate fixation with a precontoured distal clavicular plate or a 'hook' plate within 28 days from injury)
Trial: 34128498
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (standard shoulder sling, followed by pendulum or gentle range of motion shoulder exercises)
Trial: 32920032
Drug: water soluble
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water soluble gel
Trial: 34195206
Drug: Short-term low-dose
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term low-dose lithium therapy for three consecutive days
Trial: 34195206
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for three consecutive days
Trial: 34649083
Drug: Control 'treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control 'treatment as usual' (TAU)
Trial: 35678020
Drug: Argatroban plus
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban plus dual antiplatelet therapy (DAPT)
Trial: 33337738
Drug: Gadoterate administration
RxNorm normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoterate administration after premedication with corticosteroid and diphenhydramine
Trial: 33337738
Drug: Gadoterate administration
RxNorm normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoterate administration with corticosteroid premedication
Trial: 33337738
Drug: Gadoterate administration
RxNorm normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoterate administration without corticosteroid premedication
Trial: 32925623
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral E2 with or without vaginal progesterone
Trial: 38800802
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus chemotherapy
Trial: 34098728
Drug: Abdominal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal treatment
Trial: 34098728
Drug: Combined with
RxNorm normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined with oral use of tamsulosin at 0.4 mg daily
Trial: 33683016
Drug: Drug being
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug being tested to prevent hypertensive complications
Trial: 32819842
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta 10.0 µg
Trial: 32819842
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta 10.3 µg
Trial: 32819842
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta 9.7 µg
Trial: 32819842
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta 9.3 µg
Trial: 32819842
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta 9.5–10.4 µg
Trial: 35246827
Drug: fosaprepitant 150
RxNorm normalized name: fosaprepitant 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosaprepitant 150 mg
Trial: 38697155
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of physician's choice
Trial: 34020596
Drug: Conventional Fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Fluid Therapy (CFT)
Trial: 32928560
Drug: Quercetin 75
RxNorm normalized name: vitamin A/vitamin C/vitamin D3/zinc/acetylcysteine/quercetin 750 mcg-150 mg-31.25 mcg-10 mg-300 mg-100 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 75 μg/ml (Q75)
Trial: 32928560
Drug: Quercetin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 150 μg/ml (Q150)
Trial: 32928560
Drug: Quercetin 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 300 μg/ml (Q300)
Trial: 32122219
Drug: Anakinra once
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra once daily (N=33)
Trial: 32122219
Drug: Anakinra twice
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra twice daily (N=31)
Trial: 32122219
Drug: Anakinra (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (both dosing regimens combined)
Trial: 35470813
Drug: Stepped-care cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care cognitive behavioral therapy for tinnitus
Trial: 33545015
Drug: Hexavalent rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent rotavirus vaccine
Trial: 35768167
Drug: SCPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCPB with 10 mL of 0.5% ropivacaine
Trial: 32423512
Drug: Dasotraline 6
RxNorm normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline 6 mg/d
Trial: 32423512
Drug: Dasotraline 4
RxNorm normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline 4 mg/d
Trial: 616083736
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL)
Trial: 616083736
Drug: Low-dose bevacizumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL)
Trial: 34810296
Drug: TJP-008 (1-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJP-008 (1-day split dose)
Trial: 34810296
Drug: TJP-008 (2-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJP-008 (2-day split dose)
Trial: 34810296
Drug: 2L PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2L PEG with ascorbate (2-day split dose)
Trial: 33150732
Drug: Tailored habituation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored habituation protocol for MRI including gradual exposure to scanner noise, social stories booklet, positive incentive strategies, and Play Therapy support
Trial: 32044802
Drug: Anterior suprascapular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior suprascapular block with 15 ml of ropivacaine 0.5% and epinephrine
Trial: 32044802
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block with 15 ml of ropivacaine 0.5% and epinephrine
Trial: 33441355
Drug: SPA intervention
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPA intervention (10 weekly singing group sessions led by a music facilitator)
Trial: 35926824
Drug: GSP301 nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSP301 nasal spray (olopatadine hydrochloride 665 μg and mometasone furoate 25 μg), 1 spray/each nostril twice daily for 14 days
Trial: 35926824
Drug: GSP301 nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSP301 nasal spray
Trial: 32011642
Drug: tPA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA and DNase (4 mg tPA and 5 mg DNase)
Trial: 32011642
Drug: tPA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA and placebo (5 mL normal saline)
Trial: 35883930
Drug: Specially designed
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specially designed physical therapy program
Trial: 34397596
Drug: Sequential Feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Feeding (SF)
Trial: 35819944
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin G (BPG)
Trial: 34113095
Drug: Nemiralisib 750
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemiralisib 750 µg
Trial: 34113095
Drug: Nemiralisib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemiralisib (all doses)
Trial: 34325670
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 25mcg every 2 hours
Trial: 34325670
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (titrated)
Trial: 35220473
Drug: Melatonin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (4 mg, n = 419)
Trial: 35639646
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg twice/day) and folic acid (400 μg /day)
Trial: 35639646
Drug: Inofolic (inositol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inofolic (inositol + olic acid 200 μg twice/day)
Trial: 34418398
Drug: Bexarotene (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexarotene (300 mg/m2 per day for 6 months)
Trial: 35241690
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil
Trial: 36452175
Drug: ENTF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENTF therapy (1–100 Hz, < 1 G), 40 min active treatment 5 days/week for 8 weeks; 3 treatments accompanied by 10 min of concurrent physical/occupational therapy.
Trial: 36452175
Drug: Sham treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment, 40 min treatment 5 days/week for 8 weeks.
Trial: 36452175
Drug: ENTF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENTF therapy
Trial: 32106807
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose meropenem (3 g q8h)
Trial: 32106807
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose meropenem (2 g q8h)
Trial: 36364809
Drug: Personalized vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized vitamin D3 loading dose followed by daily 2000 IU
Trial: 35667073
Drug: Intra-articular glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular glucocorticoid injection